GHK (Glycyl-L-Histidyl-L-Lysine)
glycyl-L-histidyl-L-lysine
GHK is a naturally occurring human tripeptide that declines with age, modulates expression of 4,000+ genes toward younger patterns per computational analysis (PMID 24704744), and has its strongest clinical evidence for topical skin regeneration and wound healing via the copper complex GHK-Cu (PMID 15931022; PMID 26236730; NCT07437586).
Last updated: 2026-03-10
Safety Summary
Topical GHK-Cu has a safety record built on decades of cosmeceutical use. A safety review cited by EXA-016ff8adf208 analyzed 12 studies (n=512) and reported transient erythema in 4.2% and pruritus in 2.8% of subjects, with no systemic effects consistently reported. Plasma copper levels remained unchanged in monitored trials. A post-marketing surveillance dataset (n=1,200 users) reported <1% contact dermatitis. Formal approved-label safety language and FAERS case signals were not found in the available corpus. GHK is a naturally occurring endogenous human peptide, contributing to its favorable tolerability. No documented cases of systemic toxicity from topical use in published literature. Important caveat: the specific safety review statistics (4.2%, 2.8%, n=512, n=1,200) come from a commercial vendor source (Nationwide Peptides / EXA-016ff8adf208), and the specific PMIDs cited by that source could not be independently verified in the downloaded papers. Community discussion mentions red and painful subcutaneous injection sites, but this remains anecdotal self-experimentation.
Known Side Effects
common
uncommon
rare
rare
Who Should NOT Use This
GHK binds copper with high affinity. Topical or systemic use may affect copper metabolism in patients with Wilson's disease. The active wound-healing trial (NCT07437586) excludes participants with known allergy or sensitivity to copper. Clinical implications not studied in this population.
Standard precaution for copper-containing peptide products. The active wound-healing trial excludes participants with known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings.
Pregnancy-specific safety data were not established in the supplied literature. The active wound-healing trial excludes pregnant or breastfeeding participants (NCT07437586). Topical peptide safety in pregnancy has not been systematically studied.
GHK-Cu is unstable at low pH and degrades when combined with strong acids. Copper ions catalyze the oxidation of ascorbic acid. Do not apply simultaneously. Alternate application times or use vitamin C as sodium ascorbyl phosphate (higher pH, more compatible).
Talk to Your Doctor
Before considering GHK (Glycyl-L-Histidyl-L-Lysine), discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-11]
Evidence Assessment
Tier 3 (Phase 2 RCT data or multiple smaller human studies). A completed small RCT demonstrated statistically significant skin thickness and density improvements with topical GHK-Cu (PMID 15931022). A Phase 2 RCT of topical GHK-Cu gel for acute wound healing is currently recruiting (NCT07437586). Multiple additional small human clinical studies (n=10-71) report skin improvements with topical GHK-Cu (EXA-07d9b2e4320f; EXA-016ff8adf208). However, important caveats apply: the clinical studies are predominantly small, often industry-affiliated, and not extensively independently replicated. Much foundational research comes from a small number of laboratories, particularly the work of Loren Pickart (GHK discoverer/patent holder). The gene expression modulation data (4,000+ genes) is computational analysis (Broad Institute cMap) rather than clinical trials (PMID 24704744). Systemic anti-aging effects from injectable GHK lack RCT data. The topical skin evidence base supports Tier 3; the systemic anti-aging claims are closer to Tier 4-5. Phase B rated Tier 4, but this was overly conservative given the existing completed small RCT and multiple human studies for the topical route.
1GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPMID 26236730
Pickart L, Vasquez-Soltero JM, Margolina A - Biomed Res Int (2015) - narrative review - N/A (comprehensive review)
GHK is present in human plasma, saliva, and urine, declining with age. The GHK-Cu complex accelerates wound healing and skin repair. GHK stimulates synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinases and their inhibitors. Stimulates collagen, dermatan sulfate, chondroitin sulfate, and decorin. Restores replicative vitality to fibroblasts after radiation therapy. Attracts immune and endothelial cells to injury sites. In cosmetic products, tightens loose skin, improves elasticity, skin density, firmness, reduces fine lines, wrinkles, photodamage, and hyperpigmentation. Proposed for skin inflammation, COPD, and metastatic colon cancer. Capable of up- and downregulating at least 4,000 human genes.
Limitations: Narrative review, not primary data. Lead author (Pickart) is the original discoverer of GHK and holds patents. Gene expression claims based on Connectivity Map computational analysis. Clinical claims summarize existing literature without new data. Often blends free GHK with GHK-Cu rather than cleanly separating them.
2Clinical evaluation of topical copper peptide in photoaged skin: randomized controlled studyPMID 15931022
Leyden JJ et al. - Presumed J Cosmet Dermatol (exact journal cited from EXA source) (2005) - RCT - Small (exact N not confirmed in available data; women with mild-to-moderate photodamage)
Randomized, double-blind, vehicle-controlled study demonstrated statistically significant increases in skin thickness and density after 12 weeks of twice-daily GHK-Cu cream application. Improvements measured by ultrasound biomicroscopy, providing objective structural endpoint.
Limitations: Small sample. Exact sample size not confirmed from available source data. Industry-supported study. Only topical application assessed. Cited via EXA-07d9b2e4320f secondary source.
3GHK-Cu stimulates TGF-beta1 secretion and collagen production in human fibroblastsPMID 22372789
Not confirmed - Not confirmed (2012) - in vitro (human fibroblast cultures) - In vitro
Demonstrated that GHK-Cu stimulates TGF-beta1 secretion by fibroblasts, driving transcription of collagen I and collagen III genes. Effects observed at concentrations achievable through topical application.
Limitations: In vitro study. PMID cited via EXA-07d9b2e4320f secondary source; full paper not available in downloaded source data for independent verification.
4The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of agingPMID 22585766
Pickart L et al. - Oxid Med Cell Longev (inferred) (2012) - review / computational analysis - N/A
GHK-Cu upregulates superoxide dismutase (SOD) and catalase (CAT) expression. Characterized antioxidant pathway activation extensively. Discusses prevention of oxidative stress and degenerative conditions.
Limitations: Review/computational analysis. PMID cited via EXA-07d9b2e4320f secondary source. Lead author is GHK discoverer.
5Tripeptide-copper complex GHK-Cu stimulates matrix metalloproteinases and promotes tissue remodelingPMID 10485305
Not confirmed - Not confirmed (1999) - in vitro - In vitro
GHK-Cu activates MMP-1, MMP-2, and MMP-9 for tissue remodeling. These metalloproteinases break down damaged or disorganized collagen, clearing the way for organized new matrix deposition.
Limitations: In vitro study. PMID cited via EXA-07d9b2e4320f secondary source; full paper not available for independent verification.
6Gene expression profiling of GHK-Cu effects: thousands of genes modulated toward younger patternsPMID 24704744
Pickart L et al. (inferred) - BioMed Research International (inferred) (2014) - computational analysis (Connectivity Map) - Computational (Broad Institute Connectivity Map database)
Transcriptomic analysis showed GHK-Cu shifts expression of thousands of genes in aged cells toward patterns characteristic of younger tissue. Approximately 4,000+ genes affected, representing 31% of genes showing age-related changes.
Limitations: Computational analysis of gene expression databases, not a clinical trial. Functional significance of individual gene expression changes in human skin requires further validation. PMID cited via EXA-07d9b2e4320f secondary source. Lead author is GHK discoverer.
7Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataPMID 30002421
Pickart L, Margolina A - Int J Mol Sci (2018) - review - N/A (review)
Updated review of GHK-Cu incorporating gene expression data. Discusses regenerative and protective actions across multiple systems. Covers wound healing, collagen synthesis, anti-inflammatory effects, and gene expression modulation.
Limitations: Review paper. Lead author is GHK discoverer and patent holder. Referenced by EXA-427fb779799e and EXA-b55969691b41.
8[Regulation of cell activity by the extracellular matrix: the concept of matrikines]PMID 10689625
Maquart FX et al. - Not confirmed (French-language publication) (2000) - narrative review (French-language with English abstract) - N/A
Introduced the concept of matrikines -- biologically active peptides derived from extracellular matrix degradation. GHK identified as a key matrikine with biological signaling activity arising from collagen degradation. Describes GHK as a potent activator of extracellular-matrix synthesis and remodeling.
Limitations: French-language paper. Only abstract available in English. Conceptual framework paper, no interventional data.
9Topical GHK-Cu Gel for Acute Skin Wound HealingNCT07437586
Hudson Biotech (sponsor) - ClinicalTrials.gov (2026) - Phase 2 RCT (randomized, double-blind, vehicle-controlled, split-wound; currently recruiting) - 60 estimated healthy adults
Testing 0.1% topical GHK-Cu gel applied once daily for 14 days versus vehicle on paired punch-biopsy wounds, with time to complete re-epithelialization over 21 days as the primary endpoint. Scar review at week 12.
Limitations: Study is ongoing, no results available. Industry sponsor. Uses healthy volunteers rather than chronic wounds. Tests copper complex GHK-Cu rather than free GHK.
10Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin TypesNCT05932732
Austin Institute for Clinical Research (collaborator: HydraFacial) - ClinicalTrials.gov (2024) - Phase 4, open-label interventional study (completed) - 27 actual participants
Facial-skin study in which the ReGen-GF booster included Cu-GHK along with other peptides, vitamin C derivative, hyaluronic acid, device-based Hydrafacial treatment, and red LED exposure. Listed endpoints included elasticity, wrinkles, hydration, transepidermal water loss, and tolerability through day 85.
Limitations: No results posted in available corpus. Intervention is highly confounded and does not isolate Cu-GHK. Open-label design. Collaborator is the HydraFacial company.
11GHK as co-former in co-amorphous pharmaceutical systemsPMID 41771428
Not confirmed - Not confirmed (2026) - pharmaceutical formulation study - N/A (formulation study)
Investigated GHK as a co-former in co-amorphous pharmaceutical systems, exploring its pharmaceutical applications beyond peptide therapeutics.
Limitations: Formulation study, not a therapeutic efficacy study. Recent 2026 publication.